Coral-Hinostroza Gladis N, Ytrestøyl Trine, Ruyter Bente, Bjerkeng Bjørn
AKVAFORSK, Institute of Aquaculture Research AS, N-6600 Sunndalsøra, Norway.
Comp Biochem Physiol C Toxicol Pharmacol. 2004 Oct;139(1-3):99-110. doi: 10.1016/j.cca.2004.09.011.
Appearance, pharmacokinetics and distribution of astaxanthin all-E-, 9Z- and 13Z-geometrical and (3R,3'R)-, (3R,3'S)- and (3S,3'S)-optical isomers in plasma fractions were studied in three middle-aged male volunteers (41-50 years) after ingestion of a single meal containing first a 10-mg dose equivalent of astaxanthin from astaxanthin diesters, followed by a dose of 100 mg astaxanthin equivalents after 4 weeks. Direct resolution of geometrical isomers and optical isomers of astaxanthin dicamphanates by HPLC after saponification showed that the astaxanthin consisted of 95.2% all-E-, 1.2% 9Z- and 3.6% 13Z-astaxanthin, of (3R,3'R)-, (3R,3'S; meso)- and (3S,3'S)-astaxanthin in a 31:49:20 ratio. The plasma astaxanthin concentration-time curves were measured during 76 h. Astaxanthin esters were not detected in plasma. Maximum levels of astaxanthin (C(max)=0.28+/-0.1 mg/l) were reached 11.5 h after administration and the plasma astaxanthin elimination half-life was 52+/-40 h. The C(max) at the low dose was 0.08 mg/l and showed that, the dose response was non-linear. The (3R,3'R)-astaxanthin optical isomer accumulated selectively in plasma compared to the (3R,3'S)- and (3S,3'S)-isomers, and comprised 54% of total astaxanthin in the blood and only 31% of total astaxanthin in the administered dose. The astaxanthin Z-isomers were absorbed selectively into plasma and comprised approximately 32% of total astaxanthin 6-7.5 h postprandially. The proportion of all-E-astaxanthin was significantly higher in the very low density lipoproteins and chylomicrons (VLDL/CM) plasma lipoprotein fraction than in the high density lipoproteins (HDL) and low denisty lipoproteins (LDL) fractions (P<0.05). The results indicate that a selective process increase the relative proportion of astaxanthin Z-isomers compared to the all-E-astaxanthin before uptake in blood and that the astaxanthin esters are hydrolyzed selectively during absorption.
在三名中年男性志愿者(41 - 50岁)中,研究了虾青素全反式、9Z-和13Z-几何异构体以及(3R,3'R)-、(3R,3'S)-和(3S,3'S)-旋光异构体在血浆组分中的外观、药代动力学和分布情况。志愿者先摄入一顿含有相当于10毫克虾青素二酯的剂量的餐食,4周后再摄入100毫克虾青素当量的剂量。皂化后通过高效液相色谱法直接分离虾青素二樟脑酸酯的几何异构体和旋光异构体,结果表明虾青素由95.2%的全反式、1.2%的9Z-和3.6%的13Z-虾青素组成,(3R,3'R)-、(3R,3'S; 内消旋)-和(3S,3'S)-虾青素的比例为31:49:20。在76小时内测量血浆虾青素浓度 - 时间曲线。血浆中未检测到虾青素酯。给药后11.5小时达到虾青素的最高水平(C(max)=0.28±0.1毫克/升),血浆虾青素消除半衰期为52±40小时低剂量时的C(max)为0.08毫克/升,表明剂量反应是非线性的。与(3R,3'S)-和(3S,3'S)-异构体相比,(3R,3'R)-虾青素旋光异构体在血浆中选择性积累,占血液中总虾青素的54%,而在给药剂量中仅占总虾青素的31%。虾青素Z-异构体选择性吸收进入血浆,餐后6 - 7.5小时约占总虾青素的32%。极低密度脂蛋白和乳糜微粒(VLDL/CM)血浆脂蛋白组分中全反式虾青素的比例显著高于高密度脂蛋白(HDL)和低密度脂蛋白(LDL)组分(P<0.05)。结果表明,在血液摄取前,一个选择性过程增加了虾青素Z-异构体相对于全反式虾青素的相对比例,并且虾青素酯在吸收过程中被选择性水解。